INSM Stock Price - Insmed Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Insmed Incorporated (INSM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Apr. 10, 2018 at 7:42 a.m. ET
on Zacks.com

3 Things In Biotech, April 1: Fate's Omens, Mallinckrodt's Trial, Insmed's Journey

Apr. 2, 2018 at 8:00 a.m. ET
on Seeking Alpha

Insmed files U.S. marketing application for inhaled amikacin for type of lung disease; shares up 2%

Mar. 29, 2018 at 11:02 a.m. ET
on Seeking Alpha

The Time To Buy Things Is When They're On Sale!

Mar. 26, 2018 at 5:05 p.m. ET
on Seeking Alpha

Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley

Mar. 21, 2018 at 8:54 a.m. ET
on benzinga.com

Benzinga's Top Upgrades, Downgrades For March 21, 2018

Mar. 21, 2018 at 8:31 a.m. ET
on benzinga.com

SA Interview: Biotechnology Investing With Juggernaut Capital

Mar. 18, 2018 at 7:30 a.m. ET
on Seeking Alpha

Insmed (INSM) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow

Mar. 15, 2018 at 2:36 p.m. ET
on Seeking Alpha

Key events next week - healthcare (continued #3)

Mar. 9, 2018 at 10:00 a.m. ET
on Seeking Alpha

New Strong Sell Stocks for March 1st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Mar. 1, 2018 at 7:42 a.m. ET
on Zacks.com

Insmed's (INSM) CEO Will Lewis on Q4 2017 Results - Earnings Call Transcript

Feb. 23, 2018 at 9:10 p.m. ET
on Seeking Alpha

10-K: INSMED INC

Feb. 23, 2018 at 8:04 a.m. ET
on Edgar Online - (EDG = 10Q, 10K)

Nexthera Capital Lp Buys Allergan PLC, Mylan NV, Merck Inc, Sells Seattle Genetics Inc, Clovis ...

Nexthera Capital Lp Buys Allergan PLC, Mylan NV, Merck Inc, Sells Seattle Genetics Inc, Clovis Oncology Inc, GlaxoSmithKline PLC

Feb. 15, 2018 at 4:38 p.m. ET
on GuruFocus.com

Aradigm: Points Of Discussion

Feb. 2, 2018 at 1:29 p.m. ET
on Seeking Alpha

Cramer Dives Into Big Tech Earnings - Cramer's Mad Money (2/1/18)

Feb. 2, 2018 at 6:09 a.m. ET
on Seeking Alpha

Biotech: The Gates Begin To Open

Jan. 26, 2018 at 10:55 a.m. ET
on Seeking Alpha

Insmed prices convertible debt offering

Jan. 24, 2018 at 6:49 a.m. ET
on Seeking Alpha

Premarket analyst action - healthcare

Jan. 18, 2018 at 7:54 a.m. ET
on Seeking Alpha

Research Report Identifies Brown & Brown, CorVel, Pacific Ethanol, HomeTrust Bancshares, FORTERRA INC, and Insmed with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

Apr. 5, 2018 at 8:01 a.m. ET
on GlobeNewswire

Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease

Apr. 3, 2018 at 7:22 a.m. ET
on ACCESSWIRE

Insmed to Present at the Cowen and Company 38th Annual Health Care Conference

Mar. 7, 2018 at 8:01 a.m. ET
on GlobeNewswire

Insmed Incorporated to Host Earnings Call

Feb. 23, 2018 at 6:48 a.m. ET
on ACCESSWIRE

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Feb. 21, 2018 at 5:26 p.m. ET
on GlobeNewswire

Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent

Feb. 20, 2018 at 8:02 a.m. ET
on GlobeNewswire

Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018

Feb. 15, 2018 at 8:01 a.m. ET
on GlobeNewswire

Market Trends Toward New Normal in Insmed, Hudson Technologies, East West, Ringcentral, Armstrong Flooring, and Host Hotels & Resorts -- Emerging Consolidated Expectations, Analyst Ratings

Feb. 12, 2018 at 7:41 a.m. ET
on GlobeNewswire

Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Feb. 7, 2018 at 4:30 p.m. ET
on GlobeNewswire

Insmed Announces Closing of Public Offering

Jan. 26, 2018 at 12:00 p.m. ET
on GlobeNewswire

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan. 24, 2018 at 5:31 p.m. ET
on GlobeNewswire

Insmed Announces Pricing of Public Offering of Convertible Senior Notes

Jan. 23, 2018 at 10:49 p.m. ET
on GlobeNewswire

Insmed Announces Proposed Public Offering of Convertible Senior Notes

Jan. 22, 2018 at 4:08 p.m. ET
on GlobeNewswire

Stock Review for Biotech's Investors -- Inovio Pharma, Insmed, Intra-Cellular Therapies, and Jazz Pharma

Jan. 22, 2018 at 6:55 a.m. ET
on PR Newswire - PRF

Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations

Jan. 3, 2018 at 4:11 p.m. ET
on GlobeNewswire

Today's Research Reports on Stocks to Watch: Horizon Pharma and Insmed Incorporated

Dec. 1, 2017 at 8:14 a.m. ET
on ACCESSWIRE

Insmed to Present at the Nasdaq 37th Annual Investor Conference

Nov. 28, 2017 at 8:01 a.m. ET
on GlobeNewswire

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Nov. 22, 2017 at 4:31 p.m. ET
on GlobeNewswire

Today's Research Reports on Stocks to Watch: Juno Therapeutics and Insmed Incorporated

Nov. 16, 2017 at 8:10 a.m. ET
on ACCESSWIRE

Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed

Nov. 9, 2017 at 6:20 a.m. ET
on PR Newswire - PRF

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 9 Full Ratings

Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley

Mar. 21, 2018 at 9:54 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For March 21, 2018

Mar. 21, 2018 at 9:32 a.m. ET
on Benzinga.com

Benzinga's Top Initiations

Mar. 15, 2016 at 9:45 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Shire PLC ADR	-2.21%	$48.89B
Vertex Pharmaceuticals Inc.	-0.08%	$40.31B
Array BioPharma Inc.	-0.14%	$2.93B
Alimera Sciences Inc.	0.00%	$78.38M
Novartis AG ADR	0.00%	$204.37B

Competitor Data Provided By

Dow	24,439.67	-23.27	-0.10%
S&P 500	2,671.57	1.43	0.05%
Nasdaq	7,144.09	-2.03	-0.03%
GlobalDow	3,076.16	-6.96	-0.23%
Gold	1,325.10	-13.20	-0.99%
Oil	68.25	-0.15	-0.22%

Insmed Inc.

$ 25.33

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Insmed stock price target raised to $33 from $27 at Credit Suisse

Insmed upgraded to outperform from neutral at Credit Suisse

Insmed shares skyrocket 90% on positive late-stage results for rare lung disease therapy

Stocks

Columns

Authors

Topics

^$ 25.33